Long Term Followup of Patients Enrolled in MC1137, BEAUTY Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

140 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-01-27

Study Completion Date

2033-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study gathers information and samples for further analysis as part of the BEAUTY study. The purpose of the BEAUTY study was to better understand the reasons why or why not breast cancers respond to standard chemotherapy. Collecting samples of blood and tissue and health and treatment information from patients on the BEAUTY study may help doctors identify changes that make cancer better respond to standard chemotherapy and develop better therapies for the treatment of cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Breast Cancer Genome Guided Therapy Study (BEAUTY)

NCT02022202

Invasive Breast Cancer

COMPLETED

Evaluation of Beauty Care Before Chemotherapy in Women With Breast Cancer

NCT01459003

Breast Cancer

COMPLETED PHASE3

The Use of Molecular Breast Imaging in the Evaluation of Tumor Response to Neoadjuvant Therapy in Women With Breast Cancer

NCT01023802

Neoadjuvant Therapy Chemotherapy Hormone Replacement Therapy +1 more

COMPLETED

Low-dose Molecular Breast Imaging: Comparison of Breast Cancer Detection Rate at Initial Screening and Two-year Follow-up

NCT01723124

Breast Cancer

TERMINATED NA

Long Term Follow-Up in Patients With Stage 0-IIIC Breast Cancer

NCT04661982

Breast Cancer

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. Evaluate the association of residual cancer burden and breast cancer disease-free interval.

II. Evaluate the trajectory of circulating tumor cell (CTC) and circulating tumor-deoxyribonucleic acid (ctDNA) over time after breast cancer treatment and the association with breast cancer disease-free interval.

III. Evaluate the association of peripheral blood immune phenotype (circulating immune cell subpopulations as measured by cytometry by time-of-flight \[CyTOF\]) over time with breast cancer disease-free interval.

IV. Develop and use patient derived xenograft (PDX) models from recurrent breast cancer to identify mechanisms of treatment resistance and to study new drugs/drug combinations.

V. Evaluate changes in the genomic and proteomic landscape over time, by sequencing recurrent disease and comparing with sequencing data from the primary tumor.

VI. Assess the spatial immune micro-landscapes of pre-treatment and treated tumors.

VII. Generate autologous co-culture systems of peripheral blood immune cells and breast cancer tumor cells to study the endogenous antitumor immune response and immune evasion mechanisms.

OUTLINE:

Patients undergo collection of blood samples throughout the study. Patients may also complete questionnaires and/or undergo the collection of tissue samples throughout the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Observational (biospecimen collection, questionnaire)

Patients undergo collection of blood samples throughout the study. Patients may also complete questionnaires and undergo the collection of tissue samples throughout the study.

Biospecimen Collection

Intervention Type PROCEDURE

Undergo collection of blood and tissue samples

Questionnaire Administration

Intervention Type OTHER

Complete questionnaire

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biospecimen Collection

Undergo collection of blood and tissue samples

Intervention Type PROCEDURE

Questionnaire Administration

Complete questionnaire

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Biological Sample Collection Biospecimen Collected Specimen Collection

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* REGISTRATION - FOR PATIENTS STILL ALIVE:
* Enrolled in BEAUTY \[MC1137 (NCT02022202)\] and did not withdraw consent while enrolled on BEAUTY for either specimen collection or long-term follow-up
* Able to provide written informed consent
* REGISTRATION - FOR PATIENTS WHO HAVE DIED:
* Enrolled in MC1137 and did not withdraw consent while enrolled on BEAUTY for either specimen collection or long-term follow-up
* Existence of a family member willing to provide consent for use of archived tumor biopsies obtained after enrollment in BEAUTY

Eligible Sex

ALL

Accepts Healthy Volunteers

No